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Abstract: 
Purpose: To assess, in lung cancer patients, the effects of thoracic radiotherapy (RT) on the concentrations of 
transforming growth factor-β1 (TGF-β1) and interleukin-6 (IL-6) in the bronchoalveolar lavage (BAL) fluid. 
Methods and Materials: Eleven patients with lung cancer requiring RT as part of their treatment were studied. 
BAL was performed bilaterally before, during, and 1, 3, and 6 months after RT. Before each BAL session, the 
patient's status was assessed clinically using pulmonary function tests and an adapted late effects on normal 
tissue-subjective, objective, management, analytic (LENT-SOMA) scale, including subjective and objective 
alterations. The National Cancer Institute Common Toxicity Criteria were used to grade pneumonitis. The TGF-
β1 and IL-6 levels in the BAL fluid were determined using the Easia kit. 
Results: The TGF-β1 and IL-6 concentrations in the BAL fluid recovered from the irradiated areas were 
significantly increased by thoracic RT. The increase in TGF-β1 levels tended to be greater in the group of 
patients who developed severe pneumonitis. In the BAL fluid from the nonirradiated areas, the TGF-β1 and IL-6 
concentrations remained unchanged. 
Conclusion: The observed increase in TGF-β1 and IL-6 concentrations in the BAL fluid recovered from the 
irradiated lung areas demonstrated that these cytokines may contribute to the process leading to a radiation 
response in human lung tissue.     




Lung carcinoma is the leading cause of cancer mortality in industrialized countries (1). Although treatment of 
30-40% of patients with lung cancer includes radiotherapy (RT), lung radiation can be associated with toxicity 
that may threaten a patient's quality of life and limit the dose that can be delivered. Currently, about 20% of 
patients treated with thoracic RT will develop pulmonary symptoms secondary to radiation-induced lung injury 
such as radiation pneumonitis or pulmonary fibrosis (2, 3). 
In lung carcinoma patients, the delivery of high doses of radiation is essential to improve local control and 
survival (4). In addition, RT for lung cancer often requires the radiation of large volumes of normal tissue, 
making dose escalation even more difficult. The maximal tolerated dose of radiation that can be safely delivered 
to the lungs is limited by the tolerance of the healthy pulmonary tissue. 
The response of normal tissue to radiation is a complex process. Recent advances in molecular biology have 
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made it possible to investigate the cellular and molecular mechanisms involved in the radiation-induced response 
of healthy tissues. Radiation is associated with immediate cellular damage by generation of reactive oxygen 
species, inducing cytokine-mediated multicellular interactions that ultimately result in lung fibrosis. In animal 
models, pulmonary radiation is followed by early and persistent elevation of cytokines production. This supports 
the concept of a perpetual cascade of cytokines that prompts collagen genes to activate (5). This cascade of 
cytokines persists until the expression of late effects becomes apparent pathologically and clinically. According 
to recent human studies, changes in the blood levels of cytokines such as transforming growth factor-β1 (TGF-β1) 
or interleukin-6 (IL-6) may serve as a predictor of radiation pneumonitis (6-8). The influence of thoracic RT on 
the production of cytokines in the human lung, however, has never been examined. The present study was 
designed to assess, in lung cancer patients, the effects of RT on the concentrations of a proinflammatory 
cytokine, IL-6, and of a pro-fibrogenic cytokine, TGF-β1 in the bronchoalveolar lavage (BAL) fluid collected 
before, during, and after thoracic RT. 
METHODS AND MATERIALS 
Patients 
The institutional ethics committee approved the study protocol, and 14 patients undergoing RT for histologically 
proven lung cancer, without metastasis at diagnosis, and having a life expectancy of at least 1 year, gave their 
informed consent to participate in the study. Three patients were excluded from the final analysis because of 
inadequate BAL sampling (n = 1) or persistent right lung atelectasis (n = 1), or because the patient underwent 
surgery before RT completion (n = 1). All protocol procedures were performed in accordance with the ethical 
standards on human experimentation and the Helsinki Declaration of 1975, as revised in 1983. 
RT description 
All patients underwent CT-based treatment planning using a three-dimensional computerized RT system (ISIS, 
Institut Curie, Paris, France). The doses and target volume delineations were prescribed according to 
International Commission on Radiation Units and Measurements Report 50 recommendations. They were based 
on the gross tumor volume, clinical target volume, planning target volume, tolerance of critical organs, and the 
patients' condition. The percentage of lung volume that received doses >20 Gy (V20) or 30 Gy (V30) of the right, 
left, and both lungs was obtained from dose-volume histograms using three-dimensional treatment planning. In 6 
patients, 60 Gy was administered in 2-Gy fractions, five times weekly. Two other patients received 54 Gy in 2-
Gy fractions, five times weekly. The last 3 patients received a total dose of 48 Gy in 4-Gy fractions, three times 
weekly, in two series of six fractions given 2 weeks apart. The quoted doses were corrected for lung 
heterogeneity. The treatment was carried out within a mean period of 51 ± 11.2 days. 
Clinical, functional, and radiographic evaluations 
Medical histories and physical examinations emphasizing the respiratory system were performed before, during 
(i.e., after 50-66% of the total dose had been delivered), and 1, 3, and 6 months after RT completion. Pulmonary 
function tests, chest X-rays, and thoracic CT scans were performed at the same intervals. Clinical and 
radiographic evaluations of pulmonary injury were recorded using the late effects on normal tissue-subjective, 
objective, management, analytic (LENT-SOMA) lung grading system. Two experienced chest radiologists 
independently graded the radiographs and CT scans. The National Cancer Institute Common Toxicity Criteria 
(NCI-CTC) were used to divide patients into two groups according to the pneumonitis grade. Group 1 included 
patients with NCI-CTC Grade 0 (no radiographic change) or 1 (radiographic changes but asymptomatic or 
symptoms not requiring steroids). Group 2 included patients with NCI-CTC Grade 2 (radiographic changes and 
requiring steroids or diuretics), NCI-CTC Grade 3 (radiographic changes and requiring oxygen), or NCI-CTC 
Grade 4 pneumonitis (radiographic changes and requiring assisted ventilation). Pneumonitis, thoracic CT scans, 
and chest X-rays were graded before the cytokine levels were determined. 
Measurements of lung volumes and ventilatory mechanics were performed using a pneumotachograph and body 
plethysmograph. The pulmonary diffusing capacity was assessed by the single breath carbon monoxide test. The 
forced expiratory volume in 1 s, vital capacity, carbon monoxide diffusing capacity, and single breath carbon 
monoxide were reported as the percentage of the predicted value for normal subjects with identical 
characteristics. 
Bronchoalveolar lavage 
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BAL fluid specimens were obtained bilaterally before RT, during RT, and 1,3, and 6 months after RT 
completion, at the same intervals as the clinical and radiologic evaluations. To obtain BAL fluid, the fiberoptic 
bronchoscope was wedged into a bronchus and three aliquots of 50 mL of 0.9% sterile sodium chloride were 
successively infused. The fluid of each aliquot was recovered by gentle aspiration. The fluid recovered from the 
first aliquot was discarded, and the liquid recovered after the last two aliquots was pooled. The tubes were 
immediately immersed in a slurry of ice and transferred to the laboratory where they were centrifuged for 10 min 
at 700g. The supernatants were separated into aliquots and kept frozen at -70°C until assay. The cell pellet was 
processed and analyzed as described below. For each patient, the same sites of sampling were used throughout 
the study. In the lung with tumor, BAL was performed in an area free of tumor and receiving high doses of 
radiation. This area was in the upper lobe in 3 patients, middle lobe in 6, lingula in 1, and lower lobe in 1. In the 
opposite unaffected lung, BAL was performed in the middle lobe in 2 patients, lingula in 4, and upper lobe in 5. 
Cell counts and cytologic typing 
The cell pellet obtained after centrifugation was used for a total cell count under a microscope using a Thoma 
plaque and for cell typing after Papanicolaou staining. A differential cell count was performed on at least 300 
cells per sample. 
TGF-β1 and IL-6 assay 
Concentrations of IL-6 were measured in BAL superna-tants using the enzyme-linked immunoabsorbent assay 
with the Medgenix Easia Kit according to the protocol recommended by the manufacturer (Biosource Europe 
S.A., Fleurus, Belgium). Aliquots of BAL fluid were concentrated 10-fold, and the TGF-β1 concentration was 
determined using the TGF-β1 Easia kit from the same manufacturer. The concentrations were calculated as the 
mean of duplicate assays. 
Statistical analysis 
The results are expressed as the mean and standard deviation (SD) or as the median and range. The groups were 
compared using the Mann-Whitney U test. Repeated TGF-β1 and IL-6 values were analyzed on a log-scale using 
the general linear mixed model to test for group differences while accounting for the time effect and 
intraindividual variability. The results were considered statistically significant at the 5% critical level. 
RESULTS 
Patient characteristics 
All patients were men, with a mean age of 59 ± 10 years. The patients' clinical characteristics are summarized in 
Table 1. Three patients underwent surgery before starting RT. RT was combined with chemotherapy in 10 
patients: simultaneously in 5 patients and sequentially in 5. Chemotherapy consisted of a combination of some of 
the following drugs: cisplatin, carboplatin, ifosfamide, mitomycin C, gemcitabine, etoposide, and/or vindesine. 
The median clinical follow-up after the first session of RT was 16 months (range 4-39). All but 2 patients had a 
clinical follow-up of at least 12 months; 1 patient died of sudden hemoptysis and another 1 of cardiac failure and 
complications of steroid therapy. The mean percentage of lung volume that received a dose >20 Gy was 45.1% ± 
12.3%, 9.4% ± 4.8%, and 26.8% ± 5.6% of the lung with tumor, the unaffected lung, and both lungs, 
respectively. The corresponding values for the percentage of lung volume that received a dose >30 Gy were 
40.4% ± 12.4%, 7.1% ± 3.9%, and 23.4% ± 5.3%. 
 
Table 1. Clinical characteristics 
Variable Patients 
(n) 




UICC clinical stage 
IIB 1 
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Squamous cell carcinoma 5 
Adenocarcinoma 4 
Mixed 1 
Small cell carcinoma 1 
Tumor location 
Right lung 9 
Left lung 2 
Upper lobe 8 
Middle lobe 3 
Abbreviations: ECOG = Eastern Cooperative Oncology Group; UICC = International Union Against Cancer. 
 
Radiation pneumonitis 
In Group 1, 5 patients had NCI-CTC Grade 0 (n =1) or 1 (n = 4) pneumonitis. In Group 2, 6 patients had NCI-
CTC Grade 2 (n = 4) or Grade 3 (n = 2) pneumonitis. No patient had Grade 4 pneumonitis. The median time to 
the onset of pneumonitis was 3.1 months (range 1-8) after the beginning of RT. No statistically significant 
differences were observed in the percentage of lung volume that received a dose >20 Gy or >30 Gy between 
Groups 1 and 2. 
As shown in Table 2, the symptoms related to radiation-induced lung toxicity significantly (p < 0.0001) 
increased throughout the study period, especially in Group 2 but not Group 1. Similarly, radiation-induced 
alterations on the chest radiographs increased significantly with time, and the slope was more marked in Group 
2. The thoracic CT scans also revealed significantly increased radiation-induced alterations with time (p < 
0.0001), but no difference was observed between the two groups (Table 3). The pulmonary function tests showed 
that the forced vital capacity remained unchanged (p = 0.28) and the forced expiratory volume in 1 s and 
diffusing capacity of the lung for carbon monoxide decreased significantly with time (Table 4). Again, no group 
effect was discerned. 
 
Table 2. Effects of radiotherapy on subjective signs 
   Follow-up (mo) 
Signs Before RT During RT 1 3 6 
Dyspnea*  
All patients 0.7 ±0.9 0.7 ± 1.2 1.3 ± 1.0 1.2 ± 1.1 1.4 ± 1.1 
Group 1 0.6 ±0.5 0.4 ± 0.5 0.8 ± 0.8 0.3 ±0.5 0.5 ± 0.6 
Group 2 0.8 ± 1.2 1.0 ± 1.5 1.7 ± 1.0 2.0 ±0.7 2.2 ± 0.8 
Dyspnea, cough, thoracic pain†  
All patients 2.4 ± 1.3 1.8 ± 1.8 2.5 ± 1.8 2.7 ±2.6 2.9 ±2.6 
Group 1 2.8 ± 1.6 1.6 ± 1.5 2.0 ± 2.0 0.5 ±0.6 0.5 ± 0.6 
Group 2 2.0 ±0.9 2.0 ±2.1 3.2 ± 1.7 4.4 ±2.3 4.8 ± 1.8 
Abbreviations: RT = radiotherapy; NCI-CTC = National Cancer Institute-Common Toxicity Criteria; LENT-SOMA = late effects on normal 
tissue-subjective, objective, management, analytic. 
* Time effect (p < 0.001), group effect on slope (p = 0.0025). 
† Time effect (p = 0.0098), group effect on slope (p < 0.0001). 
Group 1 patients (n = 5) had NCI-CTC Grade 1 or less; Group 2 patients (n = 6) had NCI-CTC Grade 2 or more; signs graded according to 
LENT-SOMA scale. 
Data presented as the mean ± SD. 
 
Table 3. Radiologic alterations associated with radiotherapy 
  Follow-up (mo) Radiology 
parameter Before RT During RT 1 3 6 
Chest X-ray*  
All patients 0.0 ± 0.0 0.3 ± 0.5 0.7 ± 1.0 1.4 ± 1.4 2.1 ± 1.3 
Group 1 0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.4 0.8 ± 1.0 1.5 ± 1.3 
Published in : International Journal of Radiation, Oncology, Biology, Physics (2004) 
Status: Postprint (Author’s version) 
Group 2 0.0 ± 0.0 0.5 ± 0.5 1.2 ± 1.2 2.0 ± 1.6 2.6 ± 1.1 
Chest CT†  
All patients 0.0 ± 0.0 0.5 ± 0.6 1.0 ± 0.9 1.5 ± 0.9 2.3 ± 0.9 
Group 1 0.0 ± 0.0 0.0 ± 0.0 0.6 ± 0.5 1.3 ± 0.6 2.0 ± 1.2 
Group 2 0.0 ± 0.0 0.8 ± 0.5 1.3 ± 1.0 1.6 ± 1.1 2.6 ± 0.5 
Abbreviations as in Table 2. 
* Time effect (p < 0.0001), group effect on slope (p = 0.043). † Time effect (p < 0.0001), group effect on slope (p = 0.30). Data presented as 
the mean ± SD. 
Group 1 patients (n = 5) had NCI-CTC Grade 1 or less; Group 2 patients (n = 6) had NCI-CTC Grade 2 or more; alterations graded according 
to LENT-SOMA scale. 
 
Table 4. Effects of radiotherapy on VC, FEV1, and DLCO 
  Follow-up (mo) Pulmonary 
function test Before RT During RT 1 3 6 
VC*  
All patients 84 ± 16 90 ± 22 87 ± 17 85 ± 16 85 ± 11 
Group 1 81 ± 18 92 ± 23 88 ± 18 88 ± 2 85 ± 13 
Group 2 87 ± 16 88 ± 23 86 ± 18 82 ± 10 85 ± 10 
FEV†  
All patients 71 ± 15 76 ± 21 74 ± 21 68 ± 21 65 ± 19 
Group 1 68 ± 17 77 ± 23 72 ± 22 74 ± 23 65 ± 23 
Group 2 74 ± 15 75 ± 21 75 ± 21 63 ± 20 65 ± 19 
DLCO‡  
All patients 59 ± 19 59 ± 30 52 ± 19 52 ± 18 47 ± 21 
Group 1 66 ± 18 55 ± 7 56 ± 18 58 ± 18 47 ± 14 
Group 2 53 ± 20 62 ± 42 49 ± 21 47 ± 18 48 ± 27 
Abbreviations: VC = vital capacity; FEV1 = forced expiratory volume in 1 s; DLCO = diffusing capacity of the lung for carbon monoxide; 
other abbreviations as in Table 2. 
* Time effect (p = 0.43), group effect on slope (p = 0.52). 
† Time effect (p < 0.0001), group effect on slope (p = 0.30). 
‡ Time effect (p = 0.0031), group effect on slope (p = 0.23). 
Data presented as the mean ± SD, expressed as percentage of predicted value. 
Group 1 patients (n = 5) had NCI-CTC Grade 1 or less; Group 2 patients (n = 6) had NCI-CTC Grade 2 or more. 
 
BAL fluid characteristics and cell count 
On average, 31% ± 16% and 32% ± 14% of the injected volume was recovered from the irradiated and 
nonirradiated areas of the lung, respectively. Before RT, the protein concentration was similar in the BAL fluid 
collected from both lungs in Groups 1 and 2. The protein concentrations in BAL fluid recovered from both lungs 
remained unchanged throughout the study period in both groups. Before RT, the total number of cells collected 
in the BAL fluid from the lung with tumor did not differ from the cellularity of the BAL fluid collected from the 
contralateral lung. It did not change during the study. Macrophages accounted for 80% of the collected cells, and 
the remaining 20% were lymphocytes or neutrophiles. No statistically significant alteration of this distribution 
was observed during or after treatment in either lung. The lymphocyte concentration was higher in the BAL fluid 
recovered from the radiated areas in Group 2 patients, but this difference did not reach statistical significance (p 
= 0.087; Table 5). 
 
Table 5. Cell counts and typing in BAL fluid recovered from nonirradiated and irradiated areas 
Cytologic findings          Nonirradiated areas Irradiated areas 
Total cell number (104/mL) 
Group 1 280 ± 534 174 ± 126 
Group 2 262 ± 311 297 ± 326 
Macrophages (%) 
Group 1 87 ± 18 87 ± 21 
Group 2 75 ± 19 72 ± 24 
Lymphocytes (%) 
Group 1 6 ± 8 4 ± 5 
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Group 2 12 ± 12 13 ± 17 
Neutrophiles (%) 
Group 1 7 ± 14 9 ± 17 
Group 2 13 ± 17 15 ± 18 
Abbreviations: BAL = bronchoalveolar lavage; other abbreviations as in Table 2. 
Data presented as the mean ± SD for Group 1 (n = 5; NCI-CTC Grade 1 or less) and Group 2 (n = 6; NCI-CTC Grade 2 or more). 
 
IL-6 concentrations in BAL fluid 
Before treatment, the IL-6 level was similar in the BAL fluid recovered from nonirradiated and irradiated areas 
(15 ± 11 vs. 17 ± 12 pg/mL, respectively). RT significantly increased the IL-6 levels in the BAL fluid recovered 
from the irradiated areas (p = 0.012) but IL-6 levels remained unchanged in nonirradiated areas (Table 6 and 
Fig. 1). Moreover, the IL-6 concentrations in the BAL fluid recovered from irradiated areas were similar in both 
groups throughout the study period, as revealed by longitudinal data analysis (p = 0.34). 
TGF-β1 concentrations in BAL fluid 
Before RT, the TGF-β1 levels were comparable in the BAL fluid recovered from nonirradiated and irradiated 
areas (5.9 ± 1.7 vs. 5.5 ± 1.2 pg/mL, respectively). During the study period, the TGF-β1 levels increased 
significantly in the irradiated areas (p = 0.0053) and remained unchanged in the other side (Table 7 and Fig. 2). 
When considering the irradiated areas only (Fig. 3), the TGF-β1 levels tended to be greater (p = 0.058) in the 
group of patients with moderate to severe pneumonitis (Group 2). 
 
Table 6. IL-6 levels in BAL fluid recovered from nonirradiated and irradiated areas as a function of time 
   Follow-up (mo) 
Location* Before RT During RT 1 3 6 
Nonirradiated areas 
All patients 15 ± 11 17 ± 25 15 ± 10 20 ± 17 24 ± 32 
Group 1 13 ± 4.4 9.2 ± 4.3 17 ± 6.5 16 ± 13 32 ± 41 
Group 2 16 ± 14 26 ± 35 12 ± 12 24 ± 20 2.6 ± 1.1 
Irradiated areas 
All patients 17 ± 12 22 ± 32 121 ± 283 110 ± 226 47 ± 45 
Group 1 18 ± 9.9 12 ± 3.1 26 ± 25 28 ± 23 52 ± 62 
Group 2 16 ± 14 31 ± 43 200 ± 380 175 ± 300 42 ± 36 
Abbreviations: IL-6 = interleukin-6; BAL = bronchoalveolar lavage; other abbreviations as in Table 2. 
* Time effect (p = 0.17), radiation effect on intercept (p = 0.012), group effect on intercept (p = 0.34). 
Data presented as the mean ± SD, in picograms per milliliter. 
Group 1 patients (n = 5) had NCI-CTC Grade 1 or less; Group 2 patients (n = 6) had NCI-CTC Grade 2 or more. 
 
Table 7. TGF-β1 levels in BAL fluid recovered from nonirradiated and irradiated areas as a function of time 
   Follow-up (mo) 
Location* Before RT During RT 1 3 6 
Nonirradiated areas 
All patients 5.9 ± 1.7 5.8 ± 1.8 5.5 ±2.1 5.4 ± 1.1 5.9 ± 1.8 
Group 1 5.4 ± 1.3 5.9 ± 2.0 5.9 ± 1.5 5.1 ± 1.2 4.8 ± 0.8 
Group 2 6.3 ± 1.9 5.7 ± 1.8 5.1 ±2.7 5.6 ± 1.1 6.7 ± 2.0 
Irradiated areas† 
All patients 5.5 ± 1.2 5.3 ± 1.0 9.4 ± 8.4 6.7 ± 2.8 28 ±49 
Group 1 5.5 ± 1.2 5.4 ± 1.1 5.6 ± 1.4 6.5 ±3.1 6.8 ± 3.3 
Group 2 5.5 ± 1.2 5.2 ± 0.9 13 ± 11 6.8 ± 2.9 49 ± 68 
Abbreviations: TGF-β1 = transforming growth factor-β1; BAL = bronchoalveolar lavage; other abbreviations as in Table 2. Group 1 patients 
(n = 5) had NCI-CTC Grade 1 or less; Group 2 patients (n = 6) had Grade 2 or more.  
* Time effect (p = 0.0090), radiation effect on slope (p = 0.0053).  
† Time effect (p = 0.0036), group effect on slope (p = 0.058).  
Data presented as the mean ± SD, in picograms per milliliter. 
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Fig. 1. Comparison of IL-6 levels in BAL fluid (mean ± SEM) between irradiated and nonirradiated areas 
before, during, and after radiotherapy. 
 
 
Fig. 2. Comparison of TGF-β1 levels in BAL fluid (mean ± SEM) between irradiated and nonirradiated areas 
before, during, and after radiotherapy. 
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Fig. 3. Comparison of TGF-β1 levels in BAL fluid recovered from irradiated areas (mean ± SEM) between 





To our knowledge, this is the first study investigating, in humans, the effects of lung radiation during lung cancer 
treatment on the cytokine levels in BAL fluid. BAL is a minimally invasive procedure that offers the opportunity 
to investigate the local tissue alterations associated with lung disease. In this study, two biologic mediators were 
examined, a proinflammatory cytokine, IL-6 and a pro-fibrotic cytokine, TGF-β1. Our results clearly showed that 
the IL-6 and TGF-β1 levels in the BAL fluid collected from irradiated areas increased progressively during lung 
radiation. Moreover, we found the increase in TGF-β1 concentrations tends to be larger in the group of patients 
with moderate to severe pneumonitis (Group 2). Cellularity was not altered during the study period. 
 
IL-6 is a pleiotropic cytokine implicated in the regulation of many inflammatory and immunologic processes (9, 
10). Several cells in the lung parenchyma can synthesize this proinflammatory cytokine. These include Type II 
pneumocytes, T lymphocytes, alveolar macrophages, and lung fibroblasts (11-15). Increased IL-6 blood levels 
have been found in several inflammatory lung diseases such as allergic asthma (16), mycoplasma pneumonia 
(17), acute exacerbation of chronic obstructive pulmonary disease (18), severe adult respiratory distress 
syndrome (19, 20), and lung cancer (21). Also, the lung appears to be a producer of IL-6 in patients with an 
active inflammatory lung process (22). Several pulmonary diseases are associated with increased IL-6 levels in 
BAL fluid, including acute infectious pneumonia, interstitial pneumonia, acute complications of lung 
transplantation, acute respiratory distress syndrome, chronic obstructive pulmonary disease, and lung cancer (23-
31). 
In the present study, thoracic RT was associated with increased IL-6 levels in the BAL fluid recovered from 
irradiated areas, although they remained unchanged in the BAL fluid from the other areas. This is in agreement 
with in vitro studies demonstrating that ionizing radiation induces IL-6 mRNA in macrophages (32) and the 
trend toward increased IL-6 plasma concentrations after thoracic RT, as recently reported (8). Throughout the 
present study, the IL-6 levels were similar in patients who developed severe pneumonitis (Group 2) and in those 
who did not (Group 1). This contrasts with recent studies that found greater plasma IL-6 levels before, during, 
and after RT in patients who went on to develop pneumonitis (7, 8). This suggests that the IL-6 produced by the 
lung is not a major determinant of circulating IL-6 levels. It has been suggested that the increased circulatory 
level of IL-6 observed in lung cancer patients could be a part of the systemic inflammatory response syndrome 
(21). This discrepancy may also be related to differences in patient population or in sample size. 
TGF-β1 plays a central role in fibrotic diseases, contributing to both the influx and the activation of inflammatory 
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cells, as well as to activation of fibroblasts, to elaborate excessive extracellular matrix. Regarding pulmonary 
diseases, TGF-β1 has been shown to be involved in the process leading to idiopathic pulmonary fibrosis, 
bronchiolitis obliterans syndrome after lung transplantation, lung complications in scleroderma, pneumoconiosis 
or sarcoidis-associated pulmonary fibrosis, and airway wall remodeling in asthma (33-37). In addition, it has 
been proposed that TGF-β1 could be involved in the process leading to radiation-induced lung injury, because 
pneumonitis is associated with increased TGF-β1 plasma levels at the end of RT (38). Elevated TGF-β1 plasma 
levels at the end of RT would be a risk factor for symptomatic radiation-induced lung injury (39, 40). In contrast, 
patients with low TGF-β1 plasma levels could benefit from radiation dose escalation (6). The increased TGF-β1 
plasma levels observed in some lung cancer patients whose treatment included thoracic RT would be related to 
an increased local production of TGF-β1 resulting from the exposure of the tumor and its environment to 
radiation (41). The radiation-induced elevation of TGF-β1 levels in the BAL fluid observed in our study supports 
this hypothesis. However, a recent study failed to find any significant change in TGF-β1 plasma levels associated 
with RT (8). Mechanisms potentially responsible for this discrepancy include sample size, population, and 
methodologic differences (42). 
The increase in TGF-β1 levels in the BAL fluid recovered from the irradiated areas is in agreement with animal 
studies showing that lung radiation is associated with an increased secretion of this cytokine. In a fibrosis-prone 
mice strain, thoracic radiation induced an acute and a long-lasting increase in the expression of TGF-β1 in 
pulmonary tissue (5, 43, 44). Thoracic radiation to rats caused an increase in TGF-β1 protein concentration in 
BAL fluid that reached a maximum at between 3 and 6 weeks (45). This increase is paralleled by enhanced TGF-
β1 mRNA expression, as shown by whole lung Northern blot assay. It precedes histologically detectable 
pulmonary fibrosis, which is never apparent until 8 weeks after radiation (45). In vitro radiation of cultured rat 
lung fibroblasts increased the amount of TGF-β1 in the culture medium, and TGF-β1 would have an important 
role in triggering radiation-induced inhibition of clonogenic activity and terminal differentiation of rat lung 
fibroblasts (46). Furthermore, TGF-β1 has recently been demonstrated to be a major autocrine regulator of 
intrinsic radiation sensitivity of mouse lung fibroblasts (47). 
A significant finding of the present clinical study was that TGF-β1 levels in the BAL fluid tended to increase 
more in the group of patients who developed more severe radiation pneumonitis (Group 2), suggesting that it 
could causally contribute to the radiation-induced lung injury. Such a role has been previously demonstrated in 
experimental studies. In mice sensitive to radiation-induced pulmonary fibrosis, the mRNA abundance of TGF-
β1 increased after radiation but its level in radioresistant mice was unaffected (48). Furthermore, after radiation, 
TGF-β1 was found in more cells in the lungs of fibrosis-prone mice than in the lungs of non-fibrosis-prone mice 
(49). 
In our study, TGF-β1 remained elevated in the BAL fluid recovered from the irradiated areas for several months 
after RT completion. This finding suggests that the molecular events leading to radiation-induced lung injury 
persist for a long time after treatment. 
It would be interesting to confirm, in a larger cohort of patients, the kinetics of cytokine concentration changes 
and to test the value of IL-6 and/or TGF-β1 levels in BAL fluid from irradiated areas in predicting radiation-
induced lung injury such as radiation-induced pneumonitis or fibrosis. 
Elevated TGF-β1 plasma levels occur frequently in patients with lung cancer (42, 50, 51). TGF-β1 could be 
produced in the lung by the tumor-associated stromal cells more than by the malignant cells themselves (51). In 
our study, however, TGF-β1 levels in the BAL fluid from the tumor side and from the opposite side were similar 
before treatment. This discrepancy can be explained by the choice of the site of BAL, highly irradiated but free 
of tumor. Furthermore, one cannot rule out that TGF-β1 is secreted by the tumor exclusively in the circulation 
and not in the alveoli or airways. Finally, a β-type error cannot be excluded because of the limited number of 
patients included in the present study. 
CONCLUSION 
We performed a pilot study on a limited number of lung cancer patients to evaluate the significance of two 
cytokines, IL-6 and TGF-βl, as biologic markers useful for the prediction of radiation-induced fibrosis. We 
showed that RT increases IL-6 and TGF-β1 levels in BAL fluid collected from irradiated areas. In addition, the 
increase in TGF-β1 levels tended to be greater in patients with more severe pneumonitis (Group 2). These 
findings suggest that IL-6 and TGF-β1 are involved in the process leading to a radiation response in human lung 
tissue. 
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